RA Capital, a multi-stage investment manager, agreed to invest $200m in Novavax, a late-stage biotechnology company, at an effective purchase price per share of common stock equal to the June 12, 2020 closing price. "The global vaccine effort is searching for candidates that are capable of both generating the highest neutralizing antibody titers and large-scale production. We are excited to increase our investment in Novavax, which along with resources from CEPI and the US Department of Defense, will support Novavax in its important work developing an effective, scalable vaccine for SARS-CoV-2," Peter Kolchinsky, RA Capital Managing Partner.